These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 11858982)
1. Health Economics Unit achievements. Crott R; Neymark N Eur J Cancer; 2002 Mar; 38 Suppl 4():S147-50. PubMed ID: 11858982 [TBL] [Abstract][Full Text] [Related]
2. EORTC Brain Tumor Group: achievements and perspectives. Vecht ChJ; van den Bent MJ; Lacombe D Eur J Cancer; 2002 Mar; 38 Suppl 4():S35-8. PubMed ID: 11858962 [TBL] [Abstract][Full Text] [Related]
3. Commentary: fifty years of the European Organisation for Research and Treatment Of Cancer (EORTC)--making the difference for the European oncology community. Meunier F; Lawler M; Pinedo HM Oncologist; 2012; 17(6):e6-7. PubMed ID: 22723021 [TBL] [Abstract][Full Text] [Related]
4. The EORTC Laboratory Research Division. European Organisation for Research and Treatment of Cancer. Brünner N; Double J; Fichtner I; Gescher A; Newell D; Oosterhuis W; Price P Eur J Cancer; 2002 Mar; 38 Suppl 4():S14-8. PubMed ID: 11858958 [TBL] [Abstract][Full Text] [Related]
5. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee. Lardot C; Steward W; Van Glabbeke M; Armand JP Eur J Cancer; 2002 Mar; 38 Suppl 4():S24-30. PubMed ID: 11858960 [TBL] [Abstract][Full Text] [Related]
7. The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer. Eggermont AM; Keilholz U; Autier P; Ruiter DJ; Lehmann F; Lienard D; Eur J Cancer; 2002 Mar; 38 Suppl 4():S114-9. PubMed ID: 11858976 [TBL] [Abstract][Full Text] [Related]
8. The EORTC Genito-Urinary Tract Cancer Group: 25 years of achievements and future strategies. Bono A; Zurlo A Eur J Cancer; 2002 Mar; 38 Suppl 4():S71-4. PubMed ID: 11858969 [TBL] [Abstract][Full Text] [Related]
9. The EORTC and drug development. European Organisation for Research and Treatment of Cancer. Lacombe D; Fumoleau P; Zwierzina H; Twelves C; Hakansson L; Jayson G; Lehmann F; Verweij J; ; Eur J Cancer; 2002 Mar; 38 Suppl 4():S19-23. PubMed ID: 11858959 [TBL] [Abstract][Full Text] [Related]
10. EORTC Radiotherapy Group: achievements and future projects. European Organisation for Research and Treatment of Cancer. Budach V; Zurlo A; Horiot JC Eur J Cancer; 2002 Mar; 38 Suppl 4():S134-7. PubMed ID: 11858979 [TBL] [Abstract][Full Text] [Related]
11. Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer. Therasse P; De Mulder PH Eur J Cancer; 2002 Mar; 38 Suppl 4():S152-4. PubMed ID: 11858984 [TBL] [Abstract][Full Text] [Related]
12. Factors to consider when designing phase III clinical trials involving economic evaluations. van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753 [TBL] [Abstract][Full Text] [Related]
13. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222 [TBL] [Abstract][Full Text] [Related]
14. Highlights and strategies of the EORTC Leukemia Group. European Organisation for Research and Treatment of Cancer. de Witte T; Marie JP; Suciu S; Anak O; Eur J Cancer; 2002 Mar; 38 Suppl 4():S94-9. PubMed ID: 11858973 [TBL] [Abstract][Full Text] [Related]
15. Addressing the challenge of intergroup studies in oncology: the EORTC experience. European Organisation for Research and Treatment of Cancer. Zurlo A; Therasse P Eur J Cancer; 2002 Mar; 38 Suppl 4():S169-72. PubMed ID: 11858988 [TBL] [Abstract][Full Text] [Related]
16. The EORTC Breast Cancer Group: 40 years of research contributing to improve breast cancer management. Therasse P; Piccart M; van de Velde CJ; Jassem J; Eur J Cancer; 2002 Mar; 38 Suppl 4():S39-43. PubMed ID: 11858963 [TBL] [Abstract][Full Text] [Related]
17. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994 [TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900 [TBL] [Abstract][Full Text] [Related]
19. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. Owen JB; Grigsby PW; Caldwell TM; Konski AA; Johnson DJ; Demas WF; Movsas B; Jones CU; Wasserman TH Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):633-9. PubMed ID: 11172943 [TBL] [Abstract][Full Text] [Related]
20. The Children Leukemia Group: 30 years of research and achievements. Otten J; Philippe N; Suciu S; Béhar C; Babin-Boilletot A; Thyss A; Ferster A; Vilmer E; Eur J Cancer; 2002 Mar; 38 Suppl 4():S44-9. PubMed ID: 11858964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]